Inpharma 1227 - 4 Mar 2000

Treating patients with pulmonary embolism (PE) with dalteparin sodium on an outpatient basis is feasible, report researchers from Canada. 108 patients with PE received SC dalteparin sodium 200 U/kg once daily for ≥ 5 days on an outpatient basis; 27 patients were managed initially as inpatients, completing dalteparin sodium therapy as outpatients and the remaining 81 patients were managed entirely as outpatients. Warfarin was commenced on the day of diagnosis. Patients were followed-up for 3 months. For all outpatients, the overall symptomatic recurrence rate of venous thromboembolism was 5.6% and major bleeds were experienced by 1.9% of patients. Of a total of 4 deaths, none were attributable to PE or a major bleed.

Kovacs MJ, et al. Outpatient treatment of pulmonary embolism with dalteparin. Thrombosis and Haemostasis 83: 209-211, Feb 2000 800815393